Pipeline Insight: Cancer Overview - Breast, Gynecological, Genitourinary - Diverse drugs approaching the market for many tumor types : Market Research Report

Pipeline Insight: Cancer Overview - Breast, Gynecological, Genitourinary - Diverse drugs approaching the market for many tumor types

Published by: Datamonitor

Published: Sep. 25, 2008 - 287 Pages

CHAPTER 1 EXECUTIVE SUMMARY: Scope of the analysis; Datamonitor insight into the cancer market; Related reports; Upcoming reports
CHAPTER 2 PIPELINE OVERVIEW AND DYNAMICS: Pipeline overview; Late-phase pipeline; Pipeline by indication; Breast cancer and prostate cancer will always remain popular R&D targets, however, the niche indications are increasing in popularity
CHAPTER 3 R&D APPROACH: Classification of pipeline products; Cytotoxics; Antihormonal therapies; Molecular targeted therapies; Immunotherapeutic agents; Oncology clinical trial design
CHAPTER 4 BLADDER CANCER: Overview of bladder cancer; Definition; Bladder cancer is a common tumor type in males; Epidemiology; Incidence of bladder cancer will rise due to an increase in industrialization, lifestyle factors and an ageing population; Mortality from bladder cancer is very low in the early stages, however, rises dramatically once the tumor spreads; Treatment of bladder cancer; Unmet need in bladder cancer; Summary of unmet needs; Increase early diagnosis to enhance survival; Agents with better routes of administration in comparison with intravesical therapy; A better 'standard' for advanced disease with less toxicity is needed; Salvation of the bladder is the ideal; Pipeline overview; Pipeline summary; Late-phase pipeline; Phase II pipeline; Comparative forecasts; Definition of current comparator therapy; Pipeline candidates; Urocidin (MCC; Bioniche); Drug overview; Key historical events; Clinical development in bladder cancer; Datamonitor comments; EOquin (apaziquone; Spectrum Pharmaceuticals); Drug overview; Key historical events; Clinical development in bladder cancer; Datamonitor comments; Valstar (valrubicin; Indevus); Drug overview; Key historical events; Clinical development in bladder cancer; Datamonitor comments; Larotaxel (XRP-9881; Sanofi-Aventis); Drug overview; Key historical events; Clinical development in bladder cancer; Datamonitor comments; Satisfaction of unmet needs; Some satisfaction of unmet needs will occur, however, further research is needed in advanced disease
CHAPTER 5 BREAST CANCER: Overview of breast cancer; Definition; Breast cancer remains the most common cancer and second most common cause of cancer-related death in women worldwide; Epidemiology; Incidence of breast cancer will continue to rise as lifestyles associated with risk factors are increasingly adopted and in line with the ageing population; While mortality rates are low in comparison to incidence, absolute mortality shows breast cancer remains a leading cause of death in women; Treatment of breast cancer; Unmet need in breast cancer; Summary of unmet needs; Effective treatment for metastatic disease still remains elusive; A wider range of treatment options is necessary for hormone receptor-negative and HER-2 negative patients; Elderly patients remain underserved in terms of treatment options; More convenient and better tolerated therapies are needed; Pipeline overview; Pipeline summary; Late-phase pipeline; Phase II pipeline; Comparative forecasts; Definition of current comparator therapy; Pipeline candidates; Afinitor (everolimus; Novartis); Drug overview; Key historical events; Clinical development in breast cancer; Datamonitor comments; Armala (pazopanib; GlaxoSmithKline); Drug overview; Key historical events; Clinical development in breast cancer; Datamonitor comments; Omnitarg (pertuzumab; Genentech/Roche/Chugai); Drug overview; Key historical events; Clinical development in breast cancer; Datamonitor comments; Sutent (sunitinib; Pfizer); Drug overview; Key historical events; Clinical development in breast cancer; Datamonitor comments; Ramucirumab (IMC-1121B; ImClone); Drug overview; Key historical events; Clinical development in breast cancer; Datamonitor comments; Eribulin (E7389; Eisai); Drug overview; Key historical events; Clinical development in breast cancer; Datamonitor comments; Satisfaction of unmet needs; The four targeted therapies in late-phase development for breast cancer show promise in fulfilling some unmet need
CHAPTER 6 CERVICAL CANCER: Overview of cervical cancer; Definition; Cervical cancer constitutes 17% of all gynecological tumors; Epidemiology; Incidence rates of cervical cancer have decreased due to screening programs, however overall incidence will rise in line with the ageing population; Mortality is relatively high in comparison to incidence of cervical cancer given its propensity for early diagnosis; Treatment of cervical cancer; Unmet need in cervical cancer; Summary of unmet needs; Better systemic therapy is required for metastatic and recurrent disease; More large-scale, randomized clinical trials are necessary to define optimal treatment strategies across cervical cancer; The cervical cancer pipeline is relatively sparse; Pipeline overview; Pipeline summary; Late-phase pipeline; Phase II pipeline; Comparative forecasts; Definition of current comparator therapy; Pipeline candidates; Gemzar (gemcitabine; Eli Lilly); Drug overview; Key historical events; Clinical development in cervical cancer; Datamonitor comments; Tirazone (tirapazamine; National Cancer Institute/Stanford University/SRI International); Drug overview; Key historical events; Clinical development in cervical cancer; Datamonitor comments; Satisfaction of unmet needs; Unmet needs are unlikely to be fulfilled by the current pipeline
CHAPTER 7 OVARIAN CANCER: Overview of ovarian cancer; Definition; Ovarian cancer is the most frequent cause of cancer-related death from gynecological malignancies; Epidemiology; Incidence of ovarian cancer will rise in line with the ageing population since it affects primarily postmenopausal women; Mortality from ovarian cancer is relatively high in comparison with its incidence due to a high rate of diagnosis at Stage III disease; Treatment of ovarian cancer; Unmet need in ovarian cancer; Summary of unmet needs; Earlier rates of diagnosis are needed; Less invasive surgical techniques are required; More effective systemic therapies are needed across multiple lines of treatment; Increase level of R&D interest; Pipeline overview; Pipeline summary; Late-phase pipeline; Phase II pipeline; Comparative forecasts; Definition of current comparator therapy; Pipeline candidates; Avastin (bevacizumab; Genentech/Roche); Drug overview; Key historical events; Clinical development in ovarian cancer; Datamonitor comments; Telcyta (canfosfamide; Telik); Drug overview; Key historical events; Clinical development in ovarian cancer; Datamonitor comments; Phenoxodiol (Marshall Edwards); Drug overview; Key historical events; Clinical development in ovarian cancer; Datamonitor comments; Karenitecin (cositecan; BioNumerik); Drug overview; Key historical events; Clinical development in ovarian cancer; Datamonitor comments; Opaxio (paclitaxel poliglumex; Cell Therapeutics/Novartis); Drug overview; Key historical events; Clinical development in ovarian cancer; Datamonitor comments; Yondelis (trabectedin; PharmaMar/Johnson & Johnson); Drug overview; Key historical events; Clinical development in ovarian cancer; Datamonitor comments; Patupilone (EPO-906; Novartis); Drug overview; Key historical events; Clinical development in ovarian cancer; Datamonitor comments; Abagovomab (ACA-125; Menarini/CellControl BioMedical); Drug overview; Key historical events; Clinical development in ovarian cancer; Datamonitor comments; Satisfaction of unmet needs; Unmet needs in ovarian cancer will be fulfilled to some extent by means of providing numerous alternative treatment options
CHAPTER 8 PROSTATE CANCER: Overview of prostate cancer; Definition; The most common cancer type and second-leading cause of cancer-related death in males; Epidemiology; Incidence of prostate cancer continues to rise with advances in screening procedures; Mortality from prostate cancer is relatively low given the high propensity for early diagnosis; Treatment of prostate cancer; Unmet need in prostate cancer; Summary of unmet needs; Side effects from antihormonal therapies may affect compliance; Alternative treatment options are needed for hormone-refractory patients; Greater R&D interest is needed in terms of innovative therapies; Pipeline overview; Pipeline summary; Late-phase pipeline

Abstract

Introduction

In 2008, the six tumor types covered in this report are forecast to account for over 1.2m new cases of cancer. Collectively, the 36 different drugs in Phase III development for the six tumor types are forecast to achieve $7,049m in sales by 2017. This constitutes a significant proportion of the oncology market, thus representing ample commercial opportunities for drug developers.

Scope

Examination of the solid cancer pipeline with in-depth clinical and commercial profiles of Phase III candidates for six tumor types
Seven major pharmaceutical market sales forecasts for Phase III pipeline products through to 2017 with product-specific assumptions
Segmentation and analysis of the current solid tumor pipeline by developmental phase, drug class and indication for six tumor types
Insight and analysis of market potential including commercial opportunity, epidemiology, commonalities across cancers and discussion of unmet needs

Highlights

Avastin (bevacizumab; Genentech/Roche) has shown the greatest potential in the ovarian cancer pipeline to date, with encouraging response rates in heavily pretreated patients, alongside the commercially favorable backing of Genentech and Roche, who have considerable experience in the oncology market.

Abiraterone (CB-7630; Cougar Biotechnology/BTG) shows the greatest potential in the prostate cancer pipeline. Abiraterone shows real promise in providing an effective therapy in the second-line or higher setting among patients where all lines of antihormonal therapy and Taxotere (docetaxel; Sanofi-Aventis) have failed.

In the RCC pipeline, Afinitor (everolimus; Novartis) shows the most promise, by providing a treatment option for tyrosine kinase inhibitor-refractory patients, who currently face a lack of viable therapies. Afinitor is the first drug to show a Phase III clinical benefit in this patient population, which could have a great impact on treatment.

Reasons to Purchase

Identify key drugs and companies within the oncology pipeline based on sales forecasts to 2017 and Datamonitor drug assessment
Characterize unmet need and poorly served markets within oncology and assess the potential for pipeline products to provide satisfaction
Assess the shifting oncology market dynamic and how future treatment of solid tumors will incorporate pipeline products

Please Note: This product is delivered as a zip file

Get Full Details About This Report >>

US: 800.298.5699

Int'l: +1.240.747.3093

About MarketResearch.com
MarketResearch.com is an online aggregator selling over 160,000 market research reports, company profiles and country profiles from over 600 research firms. Our reports will provide you with the critical business and competitive intelligence you need for strategic planning and marketing research. Coverage includes the US, UK, Europe, Asia and global markets.

Pipeline Insight: Cancer Overview - Breast, Gynecological, Genitourinary - Diverse drugs approaching the market for many tumor types

Table of Contents

Abstract